|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that PPARgamma agonist inhibit cell growth of some types of human thyroid cancer.
|
11344222 |
2001 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The absence of PAX8-PPARgamma rearrangements in Hurthle cell tumors and papillary thyroid carcinomas highlights the differences in the molecular pathogenesis of these thyroid tumors.
|
12170088 |
2002 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors.
|
12970322 |
2003 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to evaluate the possibility for the therapeutic effect of PPARgamma ligands against anaplastic thyroid tumor in vitro.
|
14654945 |
2004 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objectives of the present work were: to study and compare the relative expression of PPARgamma in normal, benign and malignant thyroid tissues and to correlate PPARgamma immunostaining with clinical/pathological features of patients with thyroid cancer.
|
15238980 |
2004 |
|
Thyroid Neoplasm
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment.
|
15299084 |
2004 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genetic alterations involving the thyroid transcription factor PAX8 and the peroxisome proliferator-activated receptor gamma 1 (PPARgamma1) genes have been described in thyroid neoplasms.
|
15362967 |
2004 |
|
Thyroid Neoplasm
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Our investigations document that human thyroid cancer cell lines commonly express PPARgamma, but chromosomal translocations involving PPARgamma are uncommon.
|
15785241 |
2005 |
|
Thyroid Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our investigations document that human thyroid cancer cell lines commonly express PPARgamma, but chromosomal translocations involving PPARgamma are uncommon.
|
15785241 |
2005 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
LHGDN |
Our investigations document that human thyroid cancer cell lines commonly express PPARgamma, but chromosomal translocations involving PPARgamma are uncommon.
|
15785241 |
2005 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.
|
16219715 |
2006 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rosiglitazone is a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist that has been shown to induce differentiation, cell cycle arrest, and apoptosis in a variety of human cancers including thyroid cancer.
|
17188145 |
2006 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
LHGDN |
The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion.
|
16352687 |
2006 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using this mutant mouse, we tested the hypothesis that the peroxisome proliferator-activated receptor gamma (PPARgamma) could function as a tumor suppressor in thyroid cancer in vivo.
|
16314832 |
2006 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Here, we report our discovery of a novel CREB3L2-PPARgamma fusion mutation in thyroid carcinoma with t(3;7)(p25;q34), showing that a family of somatic PPARgamma fusion mutations exist in thyroid cancer.
|
18757431 |
2008 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As such, this article addresses the following aspects of intragenic mutations in thyroid cancer: thyroid stimulating hormone receptor and guanine-nucleotide-binding proteins of the stimulatory family mutations in hyperfunctioning tumors; mutations in RAS and other genes and aneuploidy; PAX8-PPARgamma rearrangements; BRAF mutations; mutations in oxidative phosphorylation and Krebs cycle genes in Hürthle cell tumors; mutations in succinate dehydrogenase genes in medullary carcinoma and C-cell hyperplasia; and mutations in TP53 and other genes in poorly differentiated and anaplastic carcinomas.
|
18502330 |
2008 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The common somatic genetic changes in thyroid cancer of follicular cell origin (RET/PTC, NTRK, RAS, BRAF, PAX8-PPARgamma) are generally mutually exclusive, with distinct genotype-histologic subtype of thyroid cancer and genotype-phenotype associations observed.
|
18043251 |
2008 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
LHGDN |
Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.
|
18509005 |
2008 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we report our discovery of a novel CREB3L2-PPARgamma fusion mutation in thyroid carcinoma with t(3;7)(p25;q34), showing that a family of somatic PPARgamma fusion mutations exist in thyroid cancer.
|
18757431 |
2008 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs).
|
19147628 |
2009 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Underexpression of PPARgamma is associated with aneuploidy and lower differentiation of thyroid tumours of follicular origin.
|
19724872 |
2009 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, a group of 60 follicular thyroid neoplasms [18 FTC, 1 Hurthle cell carcinoma (HCC), 24 follicular thyroid adenomas (FTA), 5 Hurthle cell adenomas (HCA), and 12 follicular variants of papillary thyroid carcinomas (FV-PTC)] were analyzed to determine the prevalence of the PAX8-PPARG translocation by fluorescence in situ hybridization.
|
19963130 |
2010 |
|
Thyroid Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements.
|
21878896 |
2011 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to develop a method for the detection of chimeric PAX8-PPARG transcripts in formalin-fixed paraffin-embedded (FFPE) thyroid tumor samples by conventional RT-PCR.
|
22179975 |
2012 |
|
Thyroid Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
TSH receptor mRNA reverse transcription-polymerase chain reaction, the Veracyte and Asuragen commercial methods, and the noncommercial use of BRAF, RAS, RET/PTC, and PAX8/PPARγ testing have promising roles in the diagnosis and treatment of patients with nodular thyroid disease and thyroid cancer.
|
22984796 |
2013 |